Sweden · Delayed Price · Currency is SEK Apotea AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 delivered 10.5% revenue growth and a 5.2% operating margin, with gross margin at a record 28.3% due to successful campaigns and improved procurement. Growth initiatives included a Norway launch and ramp-up at Varberg, while financial targets remain cautious amid global uncertainties.
Fiscal Year 2025
-
Q4 saw 7% revenue growth but weaker profitability due to campaign intensity and Varberg ramp-up costs. Full-year growth was strong at 10.1%, with major investments completed and new growth initiatives underway, including expansion into Norway.
-
Q3 saw 8.9% revenue growth, a 5% EBIT margin, and strong Rx sales, supported by the successful Varberg warehouse launch and efficiency gains. Net cash reached SEK 98 million, with a focus now shifting to external growth and leveraging new capacity.
-
Revenue grew 9.9% to SEK 1.826 billion, driven by strong RX demand and stable gross margins. Profitability improved, with an adjusted EBIT margin of 5.4%, and the Varberg facility is set to boost future efficiency. Net cash position remains strong.
-
Q1 saw 15.2% revenue growth and improved EBIT margin to 5.3%, driven by stable demand and efficiency gains. Preparations for the Varberg fulfillment center are on track, expected to boost capacity by 50%. Guidance remains cautious due to upcoming cost increases and market uncertainties.
Fiscal Year 2024
-
Q4 saw 15.8% revenue growth to SEK 1.7 billion, stable margins, and improved profitability, driven by strong Rx sales and automation. Major investments in fulfillment and AI, plus a successful IPO, position the company for further growth and efficiency gains.